Furthermore, treatment with PCSK9 inhibitors in a cohort of 26 patients with familial hypercholesterolemia, where statins and ezetimibe did not efficiently reduce LDL cholesterol, improved hepatic steatosis in those patients with a low triglyceride/HDL ratio [155]. Here, PCSK9 is linked to Hepatic steatosis.